TARA News - Candlesense

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(NASDAQ:TARA) NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for...

Compensation

3 days ago

Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, ...

Investor

10 days ago

Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, ...

Are there any indications of upcoming product launches or market expansions that could impact long‑term growth? What potential catalysts or risks could drive the stock price in the short term following this release? How does Protara's Q2 performance and pipeline outlook compare to its main competitors in the oncology and rare disease space?

Earnings

26 days ago